Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 3946 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

FDA rejects Nastech generic osteoporosis spray

During a conference call the FDA expressed a concern relating to the potential for immunogenicity that might result from a possible interaction between calcitonin-salmon, the drug’s active ingredient,

CoGenesys gets FDA OK to test heart drug in humans

Cardeva, a long-acting form of b-type natriuretic peptide (BNP), is the most advanced compound in CoGenesys’ pipeline. Preclinical studies have demonstrated that Cardeva retains the pharmacological profile of

Gilead establishes research center in Prague

The Institute of Organic Chemistry and Biochemistry (IOCB) will use the donations to establish and support the Gilead Sciences Research Centre, which will consist of selected research groups

FDA approves single pill HIV combo

The product is the first ever once-daily single pill regimen to be approved for the treatment of HIV. It combines Sustiva, manufactured by Bristol-Myers Squibb, and Truvada, manufactured

FDA cautions on illegal impotence drugs

The FDA has warned consumers not to purchase or consume Zimaxx, Libidus, Neophase, Nasutra, Vigor-25, Actra-Rx, or 4Everon, all products promoted and sold on websites as dietary supplements

MHRA advises on hospital mobile phone use

The Medicines and Healthcare products Regulatory Agency (MHRA) said that, as it continues to receive enquiries from members of the public, patients and hospital staff about the use

Stada sells US unit

Dava will pay around $40 million for the German firm’s entire stake in Stada Inc. This will comprise of approximately $5 million on the closing date, a further